Single User License
INR 136060
Site License
INR 272120
Corporate User License
INR 408180

Service Tax Additional

select a format
Price

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Head And Neck Cancer Squamous Cell Carcinoma-Pipeline Review, H1 2015

Head And Neck Cancer Squamous Cell Carcinoma-Pipeline Review, H1 2015


  Request for Sample Report

Executive Summary

Head And Neck Cancer Squamous Cell Carcinoma-Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Head And Neck Cancer Squamous Cell Carcinoma-Pipeline Review, H1 2015', provides an overview of the Head And Neck Cancer Squamous Cell Carcinoma's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Head And Neck Cancer Squamous Cell Carcinoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Head And Neck Cancer Squamous Cell Carcinoma and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Head And Neck Cancer Squamous Cell Carcinoma

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Head And Neck Cancer Squamous Cell Carcinoma and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Head And Neck Cancer Squamous Cell Carcinoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Head And Neck Cancer Squamous Cell Carcinoma pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Head And Neck Cancer Squamous Cell Carcinoma

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Head And Neck Cancer Squamous Cell Carcinoma pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 8

Introduction 10

Global Markets Direct Report Coverage 10

Head And Neck Cancer Squamous Cell Carcinoma Overview 11

Therapeutics Development 12

Pipeline Products for Head And Neck Cancer Squamous Cell Carcinoma-Overview 12

Pipeline Products for Head And Neck Cancer Squamous Cell Carcinoma-Comparative Analysis 13

Head And Neck Cancer Squamous Cell Carcinoma-Therapeutics under Development by Companies 14

Head And Neck Cancer Squamous Cell Carcinoma-Therapeutics under Investigation by Universities/Institutes 20

Head And Neck Cancer Squamous Cell Carcinoma-Pipeline Products Glance 22

Late Stage Products 22

Clinical Stage Products 23

Early Stage Products 24

Head And Neck Cancer Squamous Cell Carcinoma-Products under Development by Companies 25

Head And Neck Cancer Squamous Cell Carcinoma-Products under Investigation by Universities/Institutes 32

Head And Neck Cancer Squamous Cell Carcinoma-Companies Involved in Therapeutics Development 33

AbbVie Inc. 33

Acceleron Pharma, Inc. 34

Advaxis, Inc. 35

Altor BioScience Corporation 36

Amgen Inc. 37

Ascenta Therapeutics, Inc. 38

Astex Pharmaceuticals, Inc. 39

AstraZeneca Plc 40

AVEO Pharmaceuticals, Inc. 41

BIND Therapeutics, Inc. 42

Boehringer Ingelheim GmbH 43

Bristol-Myers Squibb Company 44

CEL-SCI Corporation 45

Celldex Therapeutics, Inc. 46

Celltrion, Inc. 47

Centrose Llc 48

Critical Outcome Technologies Inc. 49

Daiichi Sankyo Company, Limited 50

Eisai Co., Ltd. 51

Eli Lilly and Company 52

F. Hoffmann-La Roche Ltd. 53

Genentech, Inc. 54

Genexine, Inc. 55

GlaxoSmithKline Plc 56

Gliknik, Inc. 57

Glycotope GmbH 58

ImmunoGen, Inc. 59

Immunomedics, Inc. 60

Immunovative Therapies, Ltd. 61

Incyte Corporation 62

Innate Pharma SA 63

Inovio Pharmaceuticals, Inc. 64

Karyopharm Therapeutics, Inc. 65

Laboratoires Pierre Fabre SA 66

Mabion SA 67

MacroGenics, Inc. 68

MedImmune, LLC 69

Merck & Co., Inc. 70

Merck KGaA 71

Mirati Therapeutics Inc. 72

Molplex Ltd. 73

Novartis AG 74

Oncolytics Biotech Inc. 75

Onconova Therapeutics, Inc. 76

OncoSec Medical Inc. 77

Oncovir, Inc. 78

Ono Pharmaceutical Co., Ltd. 79

OXiGENE, Inc. 80

Panacea Biotec Limited 81

PCI Biotech AS 82

Pfizer Inc. 83

Shionogi & Co., Ltd. 84

Symphogen A/S 85

Synta Pharmaceuticals Corp. 86

Takara Bio Inc. 87

Threshold Pharmaceuticals, Inc. 88

VasGene Therapeutics, Inc. 89

VentiRx Pharmaceuticals, Inc. 90

Virttu Biologics Limited 91

Viventia Biotechnologies Inc. 92

Head And Neck Cancer Squamous Cell Carcinoma-Therapeutics Assessment 93

Assessment by Monotherapy Products 93

Assessment by Combination Products 94

Assessment by Target 95

Assessment by Mechanism of Action 100

Assessment by Route of Administration 104

Assessment by Molecule Type 106

Drug Profiles 108

ABBV-221-Drug Profile 108

ABT-806-Drug Profile 109

AdIL-24-Drug Profile 110

ADXS-HPV-Drug Profile 111

afatinib-Drug Profile 115

AlloVax-Drug Profile 119

alpelisib-Drug Profile 121

ALT-803-Drug Profile 123

AMG-228-Drug Profile 125

AMG-319-Drug Profile 126

Antibodies to Inhibit FRMD4A for Oncology-Drug Profile 128

Antisense Oligonucleotide to Target EGFR for Head and Neck Cancer Squamous Cell Carcinoma-Drug Profile 129

AT-406-Drug Profile 130

AV-203-Drug Profile 133

avelumab-Drug Profile 134

bleomycin sulfate-Drug Profile 136

BMS-986016-Drug Profile 138

buparlisib hydrochloride-Drug Profile 139

capmatinib-Drug Profile 143

Cell Therapy to Target EGFR for Head and Neck Cancer Squamous Cell Carcinoma-Drug Profile 145

cetuximab-Drug Profile 146

cetuximab biobetter-Drug Profile 153

cetuximab biosimilar-Drug Profile 154

cetuximab biosimilar-Drug Profile 155

cetuximab biosimilar-Drug Profile 156

cetuximab biosimilar-Drug Profile 157

COTI-2-Drug Profile 158

dalantercept-Drug Profile 161

Dendritic Cell Therapy for Oncology-Drug Profile 163

DNA IL-12-Drug Profile 165

docetaxel-Drug Profile 168

DPV-001-Drug Profile 170

DTP-348-Drug Profile 172

duligotuzumab-Drug Profile 174

durvalumab-Drug Profile 176

durvalumab + tremelimumab-Drug Profile 179

EDC-2-Drug Profile 181

enoblituzumab-Drug Profile 182

epacadostat-Drug Profile 184

everolimus-Drug Profile 186

ficlatuzumab-Drug Profile 192

futuximab-Drug Profile 195

ganetespib-Drug Profile 197

Gene Therapy to Activate p53 for Head and Neck Squamous Cell Carcinoma-Drug Profile 201

Gene Therapy to Activate p53 for Oncology-Drug Profile 202

GL-0817-Drug Profile 203

golvatinib tartrate-Drug Profile 204

GS-10-Drug Profile 206

GSK-2636771-Drug Profile 208

GSK-2849330-Drug Profile 209

GX-051-Drug Profile 210

HF-10-Drug Profile 211

HSV-1716-Drug Profile 213

IC-1001-Drug Profile 216

IMGN-289-Drug Profile 217

INO-3106-Drug Profile 218

INO-3112-Drug Profile 219

IPH-2201-Drug Profile 220

JX-929-Drug Profile 222

KGP-94-Drug Profile 223

Leukocyte Interleukin-Drug Profile 224

LGK-974-Drug Profile 227

LJM-716-Drug Profile 228

lumretuzumab-Drug Profile 230

LY-2606368-Drug Profile 232

MEDI-6469-Drug Profile 233

merestinib-Drug Profile 235

MGCD-265-Drug Profile 236

Monoclonal Antibodies to Antagonize Frizzled Receptors for Breast Cancer and Head And Neck Cancer Squamous Cell Carcinoma-Drug Profile 238

Monoclonal Antibody for Head And Neck Cancer Squamous Cell Carcinoma-Drug Profile 240

Monoclonal Antibody to Target CD147 for Pancreatic Adenocarcinoma and Head and Neck Cancer Squamous Cell Carcinoma-Drug Profile 241

motolimod-Drug Profile 242

MV-NIS-Drug Profile 244

nilotinib-Drug Profile 246

nimorazole-Drug Profile 249

nimotuzumab-Drug Profile 251

nivolumab-Drug Profile 254

olaparib-Drug Profile 260

onalespib-Drug Profile 264

Oncolytic Virus to Activate IFN-b for Hepatocellular Carcinoma and Head And Neck Cancer Squamous Cell Carcinoma-Drug Profile 267

oportuzumab monatox-Drug Profile 269

panitumumab-Drug Profile 271

patritumab-Drug Profile 274

pelareorep-Drug Profile 276

pembrolizumab-Drug Profile 281

pemetrexed disodium-Drug Profile 288

pexastimogene devacirepvec-Drug Profile 294

PF-04518600-Drug Profile 296

Poly-ICLC-Drug Profile 297

Recombinant Peptide to Target EGFR for Oncology-Drug Profile 300

Recombinant Protein for Oncology-Drug Profile 301

rigosertib sodium-Drug Profile 302

S-488210-Drug Profile 307

sacituzumab govitecan-Drug Profile 308

selinexor-Drug Profile 309

Small Molecules for Head and Neck Cancer Squamous Cell Carcinoma-Drug Profile 314

Small Molecules to Inhibit 30S RNA for Head And Neck Cancer Squamous Cell Carcinoma and Oral Cancer-Drug Profile 315

Small Molecules to Inhibit CREB Protein for Head And Neck Cancer Squamous Cell Carcinoma-Drug Profile 316

TH-4000-Drug Profile 317

trametinib dimethyl sulfoxide + uprosertib-Drug Profile 319

urelumab-Drug Profile 321

vandetanib-Drug Profile 323

varlilumab-Drug Profile 329

Vas-01-Drug Profile 331

vinflunine ditartrate-Drug Profile 333

Head And Neck Cancer Squamous Cell Carcinoma-Recent Pipeline Updates 335

Head And Neck Cancer Squamous Cell Carcinoma-Dormant Projects 493

Head And Neck Cancer Squamous Cell Carcinoma-Discontinued Products 497

Head And Neck Cancer Squamous Cell Carcinoma-Product Development Milestones 499

Featured News & Press Releases 499

Appendix 507

Methodology 507

Coverage 507

Secondary Research 507

Primary Research 507

Expert Panel Validation 507

Contact Us 507

Disclaimer 508

List of Tables

Number of Products under Development for Head And Neck Cancer Squamous Cell Carcinoma, H1 2015 19

Number of Products under Development for Head And Neck Cancer Squamous Cell Carcinoma-Comparative Analysis, H1 2015 20

Number of Products under Development by Companies, H1 2015 22

Number of Products under Development by Companies, H1 2015 (Contd..1) 23

Number of Products under Development by Companies, H1 2015 (Contd..2) 24

Number of Products under Development by Companies, H1 2015 (Contd..3) 25

Number of Products under Development by Companies, H1 2015 (Contd..4) 26

Number of Products under Investigation by Universities/Institutes, H1 2015 28

Comparative Analysis by Late Stage Development, H1 2015 29

Comparative Analysis by Clinical Stage Development, H1 2015 30

Comparative Analysis by Early Stage Development, H1 2015 31

Products under Development by Companies, H1 2015 32

Products under Development by Companies, H1 2015 (Contd..1) 33

Products under Development by Companies, H1 2015 (Contd..2) 34

Products under Development by Companies, H1 2015 (Contd..3) 35

Products under Development by Companies, H1 2015 (Contd..4) 36

Products under Development by Companies, H1 2015 (Contd..5) 37

Products under Development by Companies, H1 2015 (Contd..6) 38

Products under Investigation by Universities/Institutes, H1 2015 39

Head And Neck Cancer Squamous Cell Carcinoma-Pipeline by AbbVie Inc., H1 2015 40

Head And Neck Cancer Squamous Cell Carcinoma-Pipeline by Acceleron Pharma, Inc., H1 2015 41

Head And Neck Cancer Squamous Cell Carcinoma-Pipeline by Advaxis, Inc., H1 2015 42

Head And Neck Cancer Squamous Cell Carcinoma-Pipeline by Altor BioScience Corporation, H1 2015 43

Head And Neck Cancer Squamous Cell Carcinoma-Pipeline by Amgen Inc., H1 2015 44

Head And Neck Cancer Squamous Cell Carcinoma-Pipeline by Ascenta Therapeutics, Inc., H1 2015 45

Head And Neck Cancer Squamous Cell Carcinoma-Pipeline by Astex Pharmaceuticals, Inc., H1 2015 46

Head And Neck Cancer Squamous Cell Carcinoma-Pipeline by AstraZeneca Plc, H1 2015 47

Head And Neck Cancer Squamous Cell Carcinoma-Pipeline by AVEO Pharmaceuticals, Inc., H1 2015 48

Head And Neck Cancer Squamous Cell Carcinoma-Pipeline by BIND Therapeutics, Inc., H1 2015 49

Head And Neck Cancer Squamous Cell Carcinoma-Pipeline by Boehringer Ingelheim GmbH, H1 2015 50

Head And Neck Cancer Squamous Cell Carcinoma-Pipeline by Bristol-Myers Squibb Company, H1 2015 51

Head And Neck Cancer Squamous Cell Carcinoma-Pipeline by CEL-SCI Corporation, H1 2015 52

Head And Neck Cancer Squamous Cell Carcinoma-Pipeline by Celldex Therapeutics, Inc., H1 2015 53

Head And Neck Cancer Squamous Cell Carcinoma-Pipeline by Celltrion, Inc., H1 2015 54

Head And Neck Cancer Squamous Cell Carcinoma-Pipeline by Centrose Llc, H1 2015 55

Head And Neck Cancer Squamous Cell Carcinoma-Pipeline by Critical Outcome Technologies Inc., H1 2015 56

Head And Neck Cancer Squamous Cell Carcinoma-Pipeline by Daiichi Sankyo Company, Limited, H1 2015 57

Head And Neck Cancer Squamous Cell Carcinoma-Pipeline by Eisai Co., Ltd., H1 2015 58

Head And Neck Cancer Squamous Cell Carcinoma-Pipeline by Eli Lilly and Company, H1 2015 59

Head And Neck Cancer Squamous Cell Carcinoma-Pipeline by F. Hoffmann-La Roche Ltd., H1 2015 60

Head And Neck Cancer Squamous Cell Carcinoma-Pipeline by Genentech, Inc., H1 2015 61

Head And Neck Cancer Squamous Cell Carcinoma-Pipeline by Genexine, Inc., H1 2015 62

Head And Neck Cancer Squamous Cell Carcinoma-Pipeline by GlaxoSmithKline Plc, H1 2015 63

Head And Neck Cancer Squamous Cell Carcinoma-Pipeline by Gliknik, Inc., H1 2015 64

Head And Neck Cancer Squamous Cell Carcinoma-Pipeline by Glycotope GmbH, H1 2015 65

Head And Neck Cancer Squamous Cell Carcinoma-Pipeline by ImmunoGen, Inc., H1 2015 66

Head And Neck Cancer Squamous Cell Carcinoma-Pipeline by Immunomedics, Inc., H1 2015 67

Head And Neck Cancer Squamous Cell Carcinoma-Pipeline by Immunovative Therapies, Ltd., H1 2015 68

Head And Neck Cancer Squamous Cell Carcinoma-Pipeline by Incyte Corporation, H1 2015 69

Head And Neck Cancer Squamous Cell Carcinoma-Pipeline by Innate Pharma SA, H1 2015 70

Head And Neck Cancer Squamous Cell Carcinoma-Pipeline by Inovio Pharmaceuticals, Inc., H1 2015 71

Head And Neck Cancer Squamous Cell Carcinoma-Pipeline by Karyopharm Therapeutics, Inc., H1 2015 72

Head And Neck Cancer Squamous Cell Carcinoma-Pipeline by Laboratoires Pierre Fabre SA, H1 2015 73

Head And Neck Cancer Squamous Cell Carcinoma-Pipeline by Mabion SA, H1 2015 74

Head And Neck Cancer Squamous Cell Carcinoma-Pipeline by MacroGenics, Inc., H1 2015 75

Head And Neck Cancer Squamous Cell Carcinoma-Pipeline by MedImmune, LLC, H1 2015 76

Head And Neck Cancer Squamous Cell Carcinoma-Pipeline by Merck & Co., Inc., H1 2015 77

Head And Neck Cancer Squamous Cell Carcinoma-Pipeline by Merck KGaA, H1 2015 78

Head And Neck Cancer Squamous Cell Carcinoma-Pipeline by Mirati Therapeutics Inc., H1 2015 79

Head And Neck Cancer Squamous Cell Carcinoma-Pipeline by Molplex Ltd., H1 2015 80

Head And Neck Cancer Squamous Cell Carcinoma-Pipeline by Novartis AG, H1 2015 81

Head And Neck Cancer Squamous Cell Carcinoma-Pipeline by Oncolytics Biotech Inc., H1 2015 82

Head And Neck Cancer Squamous Cell Carcinoma-Pipeline by Onconova Therapeutics, Inc., H1 2015 83

Head And Neck Cancer Squamous Cell Carcinoma-Pipeline by OncoSec Medical Inc., H1 2015 84

Head And Neck Cancer Squamous Cell Carcinoma-Pipeline by Oncovir, Inc., H1 2015 85

Head And Neck Cancer Squamous Cell Carcinoma-Pipeline by Ono Pharmaceutical Co., Ltd., H1 2015 86

Head And Neck Cancer Squamous Cell Carcinoma-Pipeline by OXiGENE, Inc., H1 2015 87

Head And Neck Cancer Squamous Cell Carcinoma-Pipeline by Panacea Biotec Limited, H1 2015 88

Head And Neck Cancer Squamous Cell Carcinoma-Pipeline by PCI Biotech AS, H1 2015 89

Head And Neck Cancer Squamous Cell Carcinoma-Pipeline by Pfizer Inc., H1 2015 90

Head And Neck Cancer Squamous Cell Carcinoma-Pipeline by Shionogi & Co., Ltd., H1 2015 91

Head And Neck Cancer Squamous Cell Carcinoma-Pipeline by Symphogen A/S, H1 2015 92

Head And Neck Cancer Squamous Cell Carcinoma-Pipeline by Synta Pharmaceuticals Corp., H1 2015 93

Head And Neck Cancer Squamous Cell Carcinoma-Pipeline by Takara Bio Inc., H1 2015 94

Head And Neck Cancer Squamous Cell Carcinoma-Pipeline by Threshold Pharmaceuticals, Inc., H1 2015 95

Head And Neck Cancer Squamous Cell Carcinoma-Pipeline by VasGene Therapeutics, Inc., H1 2015 96

Head And Neck Cancer Squamous Cell Carcinoma-Pipeline by VentiRx Pharmaceuticals, Inc., H1 2015 97

Head And Neck Cancer Squamous Cell Carcinoma-Pipeline by Virttu Biologics Limited, H1 2015 98

Head And Neck Cancer Squamous Cell Carcinoma-Pipeline by Viventia Biotechnologies Inc., H1 2015 99

Assessment by Monotherapy Products, H1 2015 100

Assessment by Combination Products, H1 2015 101

Number of Products by Stage and Target, H1 2015 103

Number of Products by Stage and Mechanism of Action, H1 2015 108

Number of Products by Stage and Route of Administration, H1 2015 112

Number of Products by Stage and Molecule Type, H1 2015 114

Head And Neck Cancer Squamous Cell Carcinoma Therapeutics-Recent Pipeline Updates, H1 2015 342

Head And Neck Cancer Squamous Cell Carcinoma-Dormant Projects, H1 2015 500

Head And Neck Cancer Squamous Cell Carcinoma-Dormant Projects (Contd..1), H1 2015 501

Head And Neck Cancer Squamous Cell Carcinoma-Dormant Projects (Contd..2), H1 2015 502

Head And Neck Cancer Squamous Cell Carcinoma-Dormant Projects (Contd..3), H1 2015 503

Head And Neck Cancer Squamous Cell Carcinoma-Discontinued Products, H1 2015 504

Head And Neck Cancer Squamous Cell Carcinoma-Discontinued Products (Contd..1), H1 2015 505

List of Figures

Number of Products under Development for Head And Neck Cancer Squamous Cell Carcinoma, H1 2015 19

Number of Products under Development for Head And Neck Cancer Squamous Cell Carcinoma-Comparative Analysis, H1 2015 20

Number of Products under Development by Companies, H1 2015 21

Number of Products under Investigation by Universities/Institutes, H1 2015 27

Comparative Analysis by Late Stage Development, H1 2015 29

Comparative Analysis by Clinical Stage Development, H1 2015 30

Comparative Analysis by Early Stage Products, H1 2015 31

Assessment by Monotherapy Products, H1 2015 100

Assessment by Combination Products, H1 2015 101

Number of Products by Top 10 Targets, H1 2015 102

Number of Products by Stage and Top 10 Targets, H1 2015 102

Number of Products by Top 10 Mechanism of Actions, H1 2015 107

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 107

Number of Products by Top 10 Routes of Administration, H1 2015 111

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 111

Number of Products by Top 10 Molecule Types, H1 2015 113

Number of Products by Stage and Top 10 Molecule Types, H1 2015 113

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

AbbVie Inc.

Acceleron Pharma, Inc.

Advaxis, Inc.

Altor BioScience Corporation

Amgen Inc.

Ascenta Therapeutics, Inc.

Astex Pharmaceuticals, Inc.

AstraZeneca Plc

AVEO Pharmaceuticals, Inc.

BIND Therapeutics, Inc.

Boehringer Ingelheim GmbH

Bristol-Myers Squibb Company

CEL-SCI Corporation

Celldex Therapeutics, Inc.

Celltrion, Inc.

Centrose Llc

Critical Outcome Technologies Inc.

Daiichi Sankyo Company, Limited

Eisai Co., Ltd.

Eli Lilly and Company

F. Hoffmann-La Roche Ltd.

Genentech, Inc.

Genexine, Inc.

GlaxoSmithKline Plc

Gliknik, Inc.

Glycotope GmbH

ImmunoGen, Inc.

Immunomedics, Inc.

Immunovative Therapies, Ltd.

Incyte Corporation

Innate Pharma SA

Inovio Pharmaceuticals, Inc.

Karyopharm Therapeutics, Inc.

Laboratoires Pierre Fabre SA

Mabion SA

MacroGenics, Inc.

MedImmune, LLC

Merck & Co., Inc.

Merck KGaA

Mirati Therapeutics Inc.

Molplex Ltd.

Novartis AG

Oncolytics Biotech Inc.

Onconova Therapeutics, Inc.

OncoSec Medical Inc.

Oncovir, Inc.

Ono Pharmaceutical Co., Ltd.

OXiGENE, Inc.

Panacea Biotec Limited

PCI Biotech AS

Pfizer Inc.

Shionogi & Co., Ltd.

Symphogen A/S

Synta Pharmaceuticals Corp.

Takara Bio Inc.

Threshold Pharmaceuticals, Inc.

VasGene Therapeutics, Inc.

VentiRx Pharmaceuticals, Inc.

Virttu Biologics Limited

Viventia Biotechnologies Inc.

Head And Neck Cancer Squamous Cell Carcinoma Therapeutic Products under Development, Key Players in Head And Neck Cancer Squamous Cell Carcinoma Therapeutics, Head And Neck Cancer Squamous Cell Carcinoma Pipeline Overview, Head And Neck Cancer Squamous Cell Carcinoma Pipeline, Head And Neck Cancer Squamous Cell Carcinoma Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com